Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):

Abstract: This disclosure provides a method for manufacturing a silver-plated reflecting film. The method includes following steps: (1) manufacturing a reflecting polyester film layer; (2) coating a silver-plated layer on one surface of the reflecting polyester film layer by a vacuum sliver plating method, wherein the vacuum silver plating methods comprises a vacuum evaporation plating method or a vacuum sputtering silver plating method; and (3) applying a protection layer film on the silver-plated layer and obtaining the silver-plated reflecting film.

Abstract: The present disclosure provides a hydrophilic fiber membrane with a sustained-release drug, and belongs to the field of biological materials. The present disclosure provides a hydrophilic fiber membrane with a sustained-release drug, including a fiber with a core-shell structure, where a core of the fiber includes curcumin and a first spinnable polymer, and a shell of the fiber includes polyethylene glycol and a second spinnable polymer; and in the shell, the polyethylene glycol and the second spinnable polymer have a mass ratio of not greater than 1:12. In the present disclosure, the fiber membrane has a core-shell structure, the curcumin is provided in the core, and the shell prevents a rapid release of the curcumin in an early stage, thereby delaying a release rate of the curcumin to prevent the drug from forming a burst release in the early stage and causing toxic reactions.

Abstract: The present disclosure provides a fiber membrane and a preparation method and use thereof, and belongs to the field of biological materials. The fiber membrane includes a fiber with a core-shell structure, where a core of the fiber includes simvastatin and a first spinnable polymer, and a shell of the fiber includes hydroxyapatite and a second spinnable polymer. In the fiber, a release of the simvastatin mainly depends on a rate of water invasion. After water invades the fiber, the simvastatin in the fiber leaves the fiber with the diffusion of water. In the present disclosure, a barrier function of the shell prevents moisture from entering the core. Therefore, the simvastatin in the core cannot leave the fiber with the diffusion of water molecules in an early stage, and a release rate of drugs is slowed down in the early stage, thereby controlling sustained release of the drugs.

Abstract: The present invention relates to the fields of medicinal chemistry and pharmacotherapy, and specifically relates to the chemical compound of formula (I), and its racemate, R-isomer, S-isomer, pharmaceutically acceptable salt, and mixtures thereof, as well as its method for preparation, a pharmaceutical composition containing said chemical compound, and use as a lysine-specific demethylase 1 (LSD 1) inhibitor. The cyclopropylamine chemical compound to which the present invention relates may be used in the treatment of cancer.

Abstract: The present invention provides a 2-polysubstituted aromatic ring-pyrimidine derivative and an optical isomer thereof, or a pharmaceutically acceptable salt or solvate thereof, the compound, and an optical isomer thereof or a pharmaceutically thereof acceptable salts or solvates can be used in the preparation of anti-tumor drugs. The invention designs and synthesizes a series of novel small molecule Chk1 inhibitors by using N-substituted pyridin-2-aminopyrimidine obtained by structure-based virtual screening as a lead compound, and carries out Chk1 kinase inhibitory activity test. The experiment confirmed that said compounds possess potent anticancer activity, Chk1 kinase inhibitory activity, and are promising Chk1 inhibitors, and can be used as new cancer therapeutic drugs, which can be applied to treat solid tumors or hematologic tumors related to proliferative disease of human or animal.

Abstract: The present invention provides a 2-polysubstituted aromatic ring-pyrimidine derivative and an optical isomer thereof, or a pharmaceutically acceptable salt or solvate thereof, the compound, and an optical isomer thereof or a pharmaceutically thereof acceptable salts or solvates can be used in the preparation of anti-tumor drugs. The invention designs and synthesizes a series of novel small molecule Chk1 inhibitors by using N-substituted pyridin-2-aminopyrimidine obtained by structure-based virtual screening as a lead compound, and carries out Chk1 kinase inhibitory activity test. The experiment confirmed that said compounds possess potent anticancer activity, Chk1 kinase inhibitory activity, and are promising Chk1 inhibitors, and can be used as new cancer therapeutic drugs, which can be applied to treat solid tumors or hematologic tumors related to proliferative disease of human or animal.

Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):

Abstract: The present invention relates to an isoindoline compound as represented by general formula (I) and used as a CRBN regulator, and a preparation method, a pharmaceutical composition, and an application of the isoindoline compound. Specifically, a class of polysubstituted isoindoline compound provided in the present invention, as a class of CRL4CRBN E3 ubiquitin ligase regulator having a novel structure, has good anti-tumor activity and immunoregulatory activity, and can be used for preparing drugs for treating diseases associated with a CRL4CRBN E3 ubiquitin ligase.

Abstract: The present invention relates to a polysubstituted isoindoline compound as shown in general formula (I), and a preparation method, a pharmaceutical composition and the use thereof. In particular, the polysubstituted isoindoline compound is provided in the present invention as a class of novel CRL4CRBN E3 ubiquitin ligase modulators in structure, wherein same has a stronger antitumor activity and antitumor spectrum, and can be used to prepare drugs for treating CRL4CRBN E3 ligase-related diseases.

Abstract: Provided by the present disclosure are an amino quinazolinone and amino isoquinolone derivatives. It is verified by numerous experiments that the compounds provided by the present disclosure have good inhibiting effects on PI3K? and PI3K?, most of the compounds have prominent inhibiting effect on PI3K?, and show strong growth inhibiting effect on PIK3CA mutant tumor cells such as human breast cancer cell strain (MCF7). Therefore, the amino quinazolinone and amino isoquinolone derivatives according to the present disclosure can be applied in the preparation of anti-tumor and anti-inflammatory medicines, and can be used as PI3K? inhibitors in the preparation of medicines for treatment of human or animal cell proliferation related tumors, the medicines comprising the derivatives any one or more of pharmaceutically acceptable salts and solvates thereof as well as pharmaceutically acceptable carriers.

Abstract: The present invention provides a 2-polysubstituted aromatic ring-pyrimidine derivative and an optical isomer thereof, or a pharmaceutically acceptable salt or solvate thereof, the compound, and an optical isomer thereof or a pharmaceutically thereof acceptable salts or solvates can be used in the preparation of anti-tumor drugs. The invention designs and synthesizes a series of novel small molecule Chk1 inhibitors by using N-substituted pyridin-2-aminopyrimidine obtained by structure-based virtual screening as a lead compound, and carries out Chk1 kinase inhibitory activity test. The experiment confirmed that said compounds possess potent anticancer activity, Chk1 kinase inhibitory activity, and are promising Chk1 inhibitors, and can be used as new cancer therapeutic drugs, which can be applied to treat solid tumors or hematologic tumors related to proliferative disease of human or animal.

Abstract: In wireless communication systems and methods for high-speed mobility deployments, a mobility status of a communication device can be determined. For example, the speed at which the communication device is traveling can be determined (e.g. such as communication devices traveling on a high-speed transportation (HST) system). HST networks can be prioritized based on the determined mobility status of the communication device when performing a fallback communication and/or when returning from the fallback communication.

Abstract: Disclosed is an electrocardiograph (ECG) lead wire. The left electrode (120) and the right electrode (130) of the ECG lead wire are stacked and enclose an accommodation hole (101) for an electrode contact to pass through. At least one of the left electrode (120) and the right electrode (130) is made of an elastic material and/or is driven by an elastic member, so that the left electrode (120) and the right electrode (130) can move relative to each other under the action of an external force to widen the accommodation hole (101), and can move relative to each other under an elastic action force to narrow the accommodation hole (101). Since the size of the accommodation hole (101) can change, the electrode holder can be adapted to electrode contacts of various sizes on the market and makes same be firmly connected, thereby ensuring the stability and reliability of signal transmission.

Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):

Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):

Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):

Abstract: Provided is a fluorinated cyclopropylamine compound represented by formula I, a racemate thereof, an R-isomer thereof, an S-isomer thereof, a pharmaceutical salt thereof, and a mixture thereof. Also provided are pharmaceutical compositions containing the compound, a preparation method for the compound, and uses thereof as a lysine specific demethylase 1 (LSD1) inhibitor, and in the treatment of cancers.

Abstract: A 2-substituted aromatic ring-pyrimidine derivative as shown in a general formula I, and an optical isomer or a pharmaceutically acceptable salt or a solvate thereof are provided. The present invention designs and synthesizes a series of novel small molecular Chk1 inhibitors by using N-substituted pyridin-2-aminopyrimidine obtained through structure-based virtual screening as a lead compound, and carries out Chk1 kinase inhibitory activity test. The experiment confirmed that said compounds possess strong anti-cancer effect, Chk1 kinase inhibitory activity and are promising Chk1 inhibitors. The compounds can be used as new cancer therapeutic drugs, which can be applied to treat solid tumors or hematologic tumors related to proliferative disease of human or animal.

Abstract: Systems and methods are described to determine anomalies and identify segments associated with the anomalies. Surveys are collected over a period of time to create historical data. The surveys include questions related to customer experience (“CX”) and questions that can be used to divide the customers into one or more segments. When a survey is received from a customer, the scores of the survey are compared with scores of the historical data (and other currently received scores) to determine if the scores associated with a survey are associated with an anomaly. Once an anomaly is detected, the segments associated with the surveys corresponding to the anomaly are analyzed to determine which segments are associated with the anomaly. The determined segments can be used to correct, solve, or explain the anomaly.